H. Lundbeck A/S

What does Lundbeck own?
Lundbeck owns a portfolio of central nervous system pharmaceutical brands including Vyepti for migraine, Rexulti for schizophrenia and depression, Trintellix for depression, Abilify Maintena for schizophrenia, and Northera for neurogenic orthostatic hypotension. The company also owns desmoteplase, an investigational stroke drug whose development was discontinued after failed clinical trials, and bexicaserin, an investigational epilepsy treatment in phase III trials.

Is Lundbeck publicly traded?
Yes, H. Lundbeck A/S trades on Nasdaq Copenhagen under ticker LUN. The company has two share classes: HLUN A shares with voting rights and HLUN B shares without voting rights. The Lundbeck Foundation owns approximately 70% of shares. Lundbeck was listed on the Copenhagen Stock Exchange in 1999.

Who founded Lundbeck?
Lundbeck was founded on August 14, 1915 by Hans Lundbeck as a trading company in Copenhagen. The business initially supplied machinery, aluminum foil, artificial sweeteners, and photographic equipment. Hans Lundbeck died in 1943, and his wife Grete Lundbeck took over leadership in 1950, guiding the company through a period of significant growth and establishing the Lundbeck Foundation in 1954.

What is Lundbeck's main business?
Lundbeck focuses exclusively on brain diseases, developing treatments for depression, schizophrenia, Alzheimer's disease, Parkinson's disease, migraine, and epilepsy. The company researches, develops, manufactures, and sells pharmaceuticals for these neurological and psychiatric conditions. Its key growth products are Vyepti for migraine and Rexulti for schizophrenia and depression.

What happened to desmoteplase?
Desmoteplase was an investigational thrombolytic drug for acute ischemic stroke. Lundbeck purchased all remaining rights from PAION AG in 2012 for 20 million euros. The DIAS-3 phase III trial did not demonstrate significant clinical benefit, and the DIAS-4 trial was prematurely terminated after the DIAS-3 results. A pooled analysis of DIAS-3, DIAS-4, and DIAS-J showed no statistically significant improvement in functional outcomes. Development was discontinued.

What were Lundbeck's FY2025 financial results?
Lundbeck reported FY2025 revenue of DKK 24.6 billion, up 13% at constant exchange rates, achieving record revenue for the fourth consecutive year. Net profit was DKK 3.2 billion. In H1 2026, revenue grew 16% at constant exchange rates to DKK 13.6 billion, with adjusted EBITDA of DKK 4.8 billion. The company maintained full-year 2026 guidance of 7-9% revenue growth.

What is the Lundbeck Foundation?
The Lundbeck Foundation was established by Grete Lundbeck in 1954 and owns approximately 70% of Lundbeck's shares. The foundation serves a dual purpose: maintaining and expanding the Lundbeck Group and funding Danish medical research. It awards approximately DKK 500 million annually to support scientific research, education, and communication activities, creating a direct link between the company's commercial success and scientific funding.

Lundbeck was founded on August 14, 1915 by Hans Lundbeck as a trading company in Copenhagen. The business initially supplied a variety of goods to the Danish market, including machinery for manufacturing, aluminum foil, artificial sweeteners, and photographic equipment. This diversified trading approach was common for Danish import businesses of the era.

The company entered the pharmaceutical market in 1924, importing medicines and cosmetics from European and American companies. By the late 1930s, Lundbeck had begun producing its own medicinal products and established a research department. In 1937, the company developed its first original product, Epicutan, for wound healing. Production continued during World War II, though limited by raw material shortages.

Hans Lundbeck died in 1943. His wife, Grete Lundbeck, took over as both director and chair of the board in 1950. Under her leadership, the company experienced significant growth. Grete Lundbeck established the Lundbeck Foundation in 1954 and gradually transferred her shares to it. The foundation remains the company's largest shareholder, owning approximately 70% of shares, and awards approximately DKK 500 million annually to support medical research.

In 1957, Lundbeck introduced Truxal (chlorprothixene), one of the world's first antipsychotic medications, entering the brain disorders market. This established the company's focus on central nervous system treatments. From the late 1970s through the 1980s, Lundbeck divested its old agency business and became a dedicated pharmaceutical company.

In 1989, Lundbeck launched Celexa (citalopram), an antidepressant that became the cornerstone of the company's international expansion. The success of citalopram and its successor escitalopram (Cipralex) funded Lundbeck's global growth and established the company as a significant player in CNS pharmaceuticals.

Lundbeck was listed on the Copenhagen Stock Exchange (now Nasdaq Copenhagen) in 1999. The IPO created liquidity for the Lundbeck Foundation while maintaining its controlling stake. The company's shares trade under the symbol LUN, with A shares carrying voting rights and B shares being non-voting.

In 2012, Lundbeck sold a portfolio of non-core products to Recordati to focus on strategic CNS products. The company pursued acquisitions to build its pipeline, including Chelsea Therapeutics for up to $658 million in 2014 (adding Northera for neurogenic orthostatic hypotension), Prexton Therapeutics for up to 905 million euros in 2018 (adding foliglurax for Parkinson's), and Alder BioPharmaceuticals for nearly $2 billion in 2019 (adding Vyepti for migraine).

In June 2023, Charl van Zyl, formerly head of neurology solutions at UCB, was announced as the next CEO and President, succeeding Deborah Dunsire. In October 2024, Lundbeck agreed to acquire American epilepsy drug maker Longboard Pharmaceuticals for $2.6 billion, adding bexicaserin to its pipeline. In November 2025, Lundbeck lost a bidding war with Alkermes for Irish sleep disorder drugmaker Avadel Pharmaceuticals.

Lundbeck publishes sustainability reports and has established environmental and social commitments. The company's focus on brain diseases gives it a specific social mission, addressing conditions that affect hundreds of millions of people worldwide.

The Lundbeck Foundation's role as majority shareholder creates a unique governance structure. The foundation awards approximately DKK 500 million annually to Danish medical research, creating a direct link between the company's commercial success and scientific funding. This structure aligns the company's long-term interests with the broader scientific community.

Lundbeck has faced ethical controversies related to its products. The company formerly held the only license to manufacture pentobarbital (Nembutal) in the United States, a drug commonly used for lethal injection in executions. After coming under criticism, Lundbeck implemented a restricted distribution system to prevent sales to prisons in states carrying out executions. In December 2011, Lundbeck divested Nembutal and other products to Akorn Inc., which committed to continuing the restricted distribution program. Akorn declared bankruptcy in 2023.

In June 2013, the European Commission fined Lundbeck 93.8 million euros for agreements made in 2002 with generic pharmaceutical producers to delay less expensive generic versions of citalopram from entering the market. Lundbeck had offered payments and other inducements to generic companies in exchange for delaying market entry, a practice known as pay-for-delay.

Lundbeck has faced regulatory and legal challenges typical of pharmaceutical companies operating in highly regulated markets.

The European Commission's 2013 fine of 93.8 million euros for pay-for-delay agreements regarding citalopram generics was a significant enforcement action. The Commission also fined several generic producers a total of 52.2 million euros. The case highlighted practices where branded pharmaceutical companies pay generic manufacturers to delay market entry, keeping drug prices elevated.

The Nembutal controversy represented a different type of ethical challenge. As the sole US manufacturer of pentobarbital, Lundbeck faced pressure from death penalty opponents to restrict the drug's availability to prisons. The company's implementation of a restricted distribution system and subsequent divestment to Akorn addressed some concerns, though US prisons have since reported shortages of the drug.

Lundbeck's acquisition strategy has drawn scrutiny regarding valuation and execution. The $2.6 billion Longboard Pharmaceuticals acquisition in 2024 represented a significant investment in a single clinical-stage asset. The failure to acquire Avadel Pharmaceuticals in November 2025, losing to Alkermes in a bidding war, raised questions about the company's ability to execute large transactions.

The discontinuation of desmoteplase development after the DIAS-3 and DIAS-4 trials represented a significant R&D setback. Lundbeck had purchased all remaining rights to desmoteplase from PAION AG in 2012 for 20 million euros. The DIAS-3 phase III trial did not demonstrate significant clinical benefit, and DIAS-4 was prematurely terminated after the DIAS-3 results. A pooled analysis of DIAS-3, DIAS-4, and DIAS-J showed no statistically significant improvement in functional outcomes despite increased recanalization rates.